LGT Capital Partners LTD. Sells 17,090 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

LGT Capital Partners LTD. trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 11.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,475 shares of the company's stock after selling 17,090 shares during the quarter. IDEXX Laboratories comprises 2.4% of LGT Capital Partners LTD.'s portfolio, making the stock its 15th largest holding. LGT Capital Partners LTD. owned about 0.17% of IDEXX Laboratories worth $69,960,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Fifth Third Wealth Advisors LLC raised its position in shares of IDEXX Laboratories by 11.0% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 835 shares of the company's stock worth $422,000 after buying an additional 83 shares in the last quarter. Meeder Asset Management Inc. increased its stake in shares of IDEXX Laboratories by 616.0% during the third quarter. Meeder Asset Management Inc. now owns 179 shares of the company's stock valued at $90,000 after acquiring an additional 154 shares during the period. Quest Partners LLC raised its holdings in IDEXX Laboratories by 4,059.4% during the third quarter. Quest Partners LLC now owns 2,870 shares of the company's stock worth $1,450,000 after purchasing an additional 2,801 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in IDEXX Laboratories by 150.6% in the third quarter. Thrivent Financial for Lutherans now owns 108,258 shares of the company's stock worth $54,693,000 after purchasing an additional 65,050 shares during the period. Finally, Mutual of America Capital Management LLC boosted its stake in IDEXX Laboratories by 0.6% during the 3rd quarter. Mutual of America Capital Management LLC now owns 11,240 shares of the company's stock valued at $5,679,000 after purchasing an additional 68 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Piper Sandler reaffirmed a "neutral" rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a research note on Thursday, October 10th. BTIG Research started coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a "buy" rating and a $580.00 target price for the company. JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Finally, Barclays reduced their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and an average price target of $552.38.

IDEXX Laboratories Trading Down 0.7 %

NASDAQ:IDXX traded down $2.79 on Tuesday, reaching $417.04. The company's stock had a trading volume of 545,252 shares, compared to its average volume of 501,526. IDEXX Laboratories, Inc. has a 1-year low of $404.74 and a 1-year high of $583.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The firm has a market cap of $34.15 billion, a PE ratio of 40.49, a PEG ratio of 3.67 and a beta of 1.36. The business's 50-day moving average price is $467.11 and its two-hundred day moving average price is $482.44.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.53 earnings per share. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.